Tags: Drug.

Carisbamate (YKP 509 proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998 the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings) a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile.

Carisbamate.png
ATC prefix
N03
ATC suffix
AX19
CAS number
194085-75-1
FDA UNII code
P7725I9V3Z
IUPAC name
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol
PubChem
9942577

Loading...

This page contains content from the copyrighted Wikipedia article "Carisbamate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.